B-Raf Kinase V600E mutant in complex with a diarylthiazole B-Raf Inhibitor
Elena Casale, Marina Ciomei(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences), Maurizio Pulici(Nerviano Medical Sciences), Rosita Lupi(Nerviano Medical Sciences), Wilma Pastori(Nerviano Medical Sciences), D. Donati, Eduard Felder, Gabriella Traquandi(Nerviano Medical Sciences), Fabio Gasparri(Nerviano Medical Sciences), Alessandra Scolaro(Nerviano Medical Sciences), Nicolò Colombo, Enrico Pesenti, L. Corti(Nerviano Medical Sciences), C. Marchionni, Michele Modugno(Nerviano Medical Sciences), Marina Fasolini(Nerviano Medical Sciences), Arturo Galvani(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia)
Cited by 0
Related Papers
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205